Schering-Plough
This article was originally published in The Tan Sheet
Executive Summary
OTC sales jumped 31% to $56 mil. in first quarter due to "increased demand" for non-PPA products, firm says in conference call April 17. Majority of Schering's cough/cold products, including Afrin, Drixoral, Chlor-Trimeton and Coricidin, did not contain PPA prior to FDA request that firms remove ingredient from products. Foot care sales fell 13% to $79 mil. as result of heightened competition, while sun care dropped 6% to $82 mil. "due to timing issues." Net sales were $2.32 bil., down 3% from year-ago period (1% excluding exchange); net income fell 10% to $564 mil
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC